Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rad51 Recombinase | 13 | 2021 | 80 | 4.170 |
Why?
|
Homologous Recombination | 9 | 2022 | 51 | 2.580 |
Why?
|
Radiation Injuries | 3 | 2019 | 155 | 1.420 |
Why?
|
DNA Repair | 12 | 2021 | 356 | 1.280 |
Why?
|
Radiotherapy | 5 | 2019 | 328 | 1.200 |
Why?
|
Endometrial Neoplasms | 11 | 2001 | 193 | 1.120 |
Why?
|
Small Molecule Libraries | 3 | 2016 | 61 | 1.020 |
Why?
|
Neoplasms | 7 | 2016 | 2898 | 0.920 |
Why?
|
Morpholines | 3 | 2015 | 65 | 0.890 |
Why?
|
Enzyme Inhibitors | 2 | 2019 | 639 | 0.890 |
Why?
|
Transcription Factor RelB | 1 | 2022 | 7 | 0.870 |
Why?
|
Benzamides | 3 | 2015 | 229 | 0.790 |
Why?
|
Sulfonamides | 3 | 2015 | 300 | 0.730 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2019 | 109 | 0.700 |
Why?
|
Quinoxalines | 1 | 2019 | 50 | 0.680 |
Why?
|
Pyrroles | 4 | 2019 | 184 | 0.680 |
Why?
|
NF-kappa B | 1 | 2022 | 444 | 0.670 |
Why?
|
PTEN Phosphohydrolase | 1 | 2019 | 128 | 0.650 |
Why?
|
Antineoplastic Agents | 5 | 2016 | 2360 | 0.650 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2023 | 1075 | 0.620 |
Why?
|
Anthracyclines | 1 | 2017 | 37 | 0.590 |
Why?
|
DNA Helicases | 2 | 2015 | 79 | 0.590 |
Why?
|
Germ-Line Mutation | 1 | 2019 | 329 | 0.570 |
Why?
|
Sarcoma | 3 | 2019 | 215 | 0.560 |
Why?
|
Neoplasm, Residual | 1 | 2017 | 162 | 0.550 |
Why?
|
DNA Replication | 4 | 2019 | 164 | 0.530 |
Why?
|
Lung Neoplasms | 8 | 2023 | 2262 | 0.530 |
Why?
|
Enzyme Activation | 2 | 2013 | 692 | 0.510 |
Why?
|
Head and Neck Neoplasms | 2 | 2016 | 1052 | 0.490 |
Why?
|
Radiotherapy, Conformal | 2 | 2007 | 83 | 0.490 |
Why?
|
Humans | 59 | 2023 | 86643 | 0.480 |
Why?
|
Drug Therapy | 1 | 2014 | 70 | 0.470 |
Why?
|
Adenocarcinoma | 6 | 2012 | 1169 | 0.470 |
Why?
|
Radiation Injuries, Experimental | 1 | 2013 | 41 | 0.470 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 1 | 2013 | 52 | 0.470 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2019 | 1197 | 0.460 |
Why?
|
Rec A Recombinases | 1 | 2013 | 14 | 0.460 |
Why?
|
Maleimides | 1 | 2012 | 29 | 0.450 |
Why?
|
Nuclear Proteins | 2 | 2015 | 696 | 0.440 |
Why?
|
DNA Damage | 3 | 2017 | 366 | 0.440 |
Why?
|
Radiotherapy, Adjuvant | 8 | 2009 | 292 | 0.430 |
Why?
|
Escherichia coli Proteins | 1 | 2013 | 179 | 0.410 |
Why?
|
Indoles | 1 | 2013 | 318 | 0.410 |
Why?
|
DNA Breaks, Double-Stranded | 3 | 2022 | 64 | 0.410 |
Why?
|
Cisplatin | 4 | 2009 | 612 | 0.390 |
Why?
|
DNA-Binding Proteins | 4 | 2021 | 1208 | 0.390 |
Why?
|
HEK293 Cells | 4 | 2019 | 615 | 0.380 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2021 | 2438 | 0.370 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2023 | 1313 | 0.360 |
Why?
|
Neoplasm Staging | 15 | 2023 | 1939 | 0.350 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2009 | 468 | 0.350 |
Why?
|
Protein Binding | 5 | 2019 | 1456 | 0.350 |
Why?
|
Cell Survival | 4 | 2019 | 969 | 0.340 |
Why?
|
Breast Neoplasms | 3 | 2021 | 2903 | 0.340 |
Why?
|
Molecular Structure | 3 | 2019 | 287 | 0.330 |
Why?
|
Prognosis | 13 | 2021 | 3679 | 0.330 |
Why?
|
DNA | 6 | 2021 | 1294 | 0.320 |
Why?
|
Radiotherapy, High-Energy | 1 | 2007 | 49 | 0.320 |
Why?
|
Female | 35 | 2021 | 44532 | 0.320 |
Why?
|
Cranial Irradiation | 1 | 2007 | 36 | 0.310 |
Why?
|
Apoptosis | 3 | 2019 | 1683 | 0.310 |
Why?
|
Aged | 25 | 2021 | 18415 | 0.310 |
Why?
|
Follow-Up Studies | 11 | 2021 | 3640 | 0.300 |
Why?
|
Structure-Activity Relationship | 3 | 2019 | 408 | 0.300 |
Why?
|
Retrospective Studies | 19 | 2023 | 8489 | 0.290 |
Why?
|
Nasolacrimal Duct | 1 | 2006 | 2 | 0.290 |
Why?
|
Lacrimal Duct Obstruction | 1 | 2006 | 3 | 0.280 |
Why?
|
Genomic Instability | 3 | 2017 | 79 | 0.280 |
Why?
|
Intubation | 1 | 2006 | 21 | 0.280 |
Why?
|
Cell Line, Tumor | 5 | 2019 | 2426 | 0.280 |
Why?
|
Middle Aged | 27 | 2021 | 25028 | 0.280 |
Why?
|
Ovariectomy | 3 | 2001 | 81 | 0.260 |
Why?
|
Adult | 23 | 2021 | 25648 | 0.250 |
Why?
|
Hysterectomy | 3 | 2001 | 146 | 0.240 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2021 | 592 | 0.240 |
Why?
|
Multiprotein Complexes | 2 | 2021 | 95 | 0.230 |
Why?
|
Genes, p53 | 1 | 2003 | 109 | 0.220 |
Why?
|
Fractures, Spontaneous | 1 | 2023 | 11 | 0.220 |
Why?
|
Sexually Transmitted Diseases | 1 | 2004 | 91 | 0.220 |
Why?
|
Attitude to Health | 1 | 2004 | 220 | 0.220 |
Why?
|
Combined Modality Therapy | 6 | 2013 | 1686 | 0.220 |
Why?
|
Survival Analysis | 9 | 2017 | 1538 | 0.220 |
Why?
|
Treatment Outcome | 13 | 2017 | 7993 | 0.220 |
Why?
|
HIV-1 | 2 | 2015 | 163 | 0.220 |
Why?
|
Biomarkers, Tumor | 2 | 2021 | 1464 | 0.210 |
Why?
|
Adenoviridae | 1 | 2003 | 345 | 0.210 |
Why?
|
Brain Neoplasms | 1 | 2007 | 763 | 0.210 |
Why?
|
Aged, 80 and over | 15 | 2021 | 6509 | 0.200 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2003 | 164 | 0.200 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2023 | 98 | 0.200 |
Why?
|
Loss of Function Mutation | 1 | 2021 | 42 | 0.200 |
Why?
|
Pelvic Neoplasms | 1 | 2001 | 45 | 0.200 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 104 | 0.200 |
Why?
|
Orthopedic Procedures | 1 | 2023 | 128 | 0.200 |
Why?
|
Genetic Therapy | 1 | 2003 | 342 | 0.200 |
Why?
|
Orthopedics | 1 | 2023 | 124 | 0.200 |
Why?
|
Brachytherapy | 6 | 2001 | 119 | 0.200 |
Why?
|
Peptides | 1 | 2004 | 639 | 0.190 |
Why?
|
Extremities | 2 | 2013 | 167 | 0.180 |
Why?
|
Neoplasm Invasiveness | 5 | 2001 | 552 | 0.180 |
Why?
|
Ossification, Heterotopic | 1 | 2019 | 31 | 0.180 |
Why?
|
Adnexa Uteri | 1 | 1999 | 12 | 0.180 |
Why?
|
Triple Negative Breast Neoplasms | 1 | 2021 | 137 | 0.170 |
Why?
|
Cycloaddition Reaction | 1 | 2019 | 6 | 0.170 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2003 | 383 | 0.170 |
Why?
|
Radiotherapy Dosage | 4 | 2009 | 468 | 0.170 |
Why?
|
Cell Cycle Proteins | 1 | 2021 | 388 | 0.170 |
Why?
|
Soft Tissue Neoplasms | 1 | 2019 | 127 | 0.170 |
Why?
|
Prostatic Neoplasms | 2 | 2001 | 1721 | 0.170 |
Why?
|
Survival Rate | 7 | 2021 | 1863 | 0.170 |
Why?
|
Naphthyridines | 1 | 2019 | 53 | 0.160 |
Why?
|
Radiobiology | 1 | 2018 | 13 | 0.160 |
Why?
|
Oxidation-Reduction | 1 | 2019 | 373 | 0.160 |
Why?
|
Male | 17 | 2021 | 40965 | 0.160 |
Why?
|
MCF-7 Cells | 2 | 2015 | 106 | 0.150 |
Why?
|
Lymphatic Metastasis | 4 | 2012 | 486 | 0.150 |
Why?
|
Prostate-Specific Antigen | 1 | 1999 | 353 | 0.150 |
Why?
|
Dose-Response Relationship, Radiation | 3 | 2007 | 188 | 0.150 |
Why?
|
Pneumonectomy | 2 | 2011 | 196 | 0.150 |
Why?
|
Preoperative Period | 1 | 2017 | 91 | 0.150 |
Why?
|
Endosonography | 1 | 2017 | 96 | 0.150 |
Why?
|
Bronchi | 1 | 2017 | 229 | 0.140 |
Why?
|
Risk | 3 | 2004 | 674 | 0.140 |
Why?
|
Immunotherapy | 1 | 2021 | 629 | 0.140 |
Why?
|
Neuroblastoma | 1 | 2019 | 374 | 0.130 |
Why?
|
Disease-Free Survival | 6 | 2011 | 1204 | 0.130 |
Why?
|
Doxorubicin | 2 | 2009 | 295 | 0.130 |
Why?
|
Neoplasm Metastasis | 3 | 2011 | 1056 | 0.130 |
Why?
|
Radiotherapy, Image-Guided | 2 | 2012 | 56 | 0.120 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2012 | 1076 | 0.120 |
Why?
|
Neoplasm Transplantation | 1 | 2014 | 391 | 0.120 |
Why?
|
Fluorometry | 1 | 2013 | 30 | 0.120 |
Why?
|
RNA Interference | 1 | 2014 | 369 | 0.110 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2013 | 94 | 0.110 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2000 | 275 | 0.110 |
Why?
|
Mitomycin | 1 | 2012 | 29 | 0.110 |
Why?
|
Chicago | 3 | 2001 | 1379 | 0.110 |
Why?
|
Neoadjuvant Therapy | 2 | 2021 | 318 | 0.110 |
Why?
|
Stress, Physiological | 1 | 2014 | 227 | 0.110 |
Why?
|
Mice, Nude | 1 | 2014 | 790 | 0.110 |
Why?
|
Actuarial Analysis | 3 | 2001 | 66 | 0.110 |
Why?
|
DNA, Single-Stranded | 2 | 2011 | 92 | 0.110 |
Why?
|
Cross-Linking Reagents | 1 | 2012 | 86 | 0.110 |
Why?
|
Protein Subunits | 1 | 2012 | 122 | 0.100 |
Why?
|
Virus Integration | 1 | 2011 | 16 | 0.100 |
Why?
|
Carcinoma, Large Cell | 1 | 2012 | 39 | 0.100 |
Why?
|
Cystadenocarcinoma, Papillary | 2 | 2001 | 9 | 0.100 |
Why?
|
Life Tables | 2 | 2001 | 48 | 0.100 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2012 | 114 | 0.100 |
Why?
|
Signal Transduction | 1 | 2022 | 3241 | 0.100 |
Why?
|
Dinoprostone | 1 | 2011 | 69 | 0.100 |
Why?
|
Cysteine | 1 | 2012 | 135 | 0.100 |
Why?
|
Esophageal Neoplasms | 2 | 2007 | 321 | 0.100 |
Why?
|
Mice | 3 | 2019 | 11352 | 0.100 |
Why?
|
Chromatin | 1 | 2014 | 380 | 0.100 |
Why?
|
Caspase 3 | 1 | 2011 | 159 | 0.100 |
Why?
|
Animals | 4 | 2019 | 26582 | 0.100 |
Why?
|
Age Factors | 3 | 2007 | 1851 | 0.100 |
Why?
|
Child | 2 | 2016 | 6927 | 0.100 |
Why?
|
Adenocarcinoma, Clear Cell | 2 | 2001 | 62 | 0.100 |
Why?
|
Radiation Oncology | 1 | 2013 | 119 | 0.100 |
Why?
|
Multivariate Analysis | 4 | 2000 | 999 | 0.100 |
Why?
|
Binding Sites | 1 | 2012 | 1098 | 0.090 |
Why?
|
Down-Regulation | 1 | 2011 | 504 | 0.090 |
Why?
|
Epirubicin | 1 | 2009 | 14 | 0.090 |
Why?
|
Neoplasms, Experimental | 1 | 2011 | 269 | 0.090 |
Why?
|
Ifosfamide | 1 | 2009 | 49 | 0.090 |
Why?
|
Postoperative Complications | 1 | 2019 | 2207 | 0.090 |
Why?
|
Amino Acid Sequence | 2 | 2021 | 2062 | 0.090 |
Why?
|
History, 19th Century | 1 | 2009 | 59 | 0.080 |
Why?
|
Necrosis | 1 | 2009 | 204 | 0.080 |
Why?
|
Enzyme Stability | 1 | 2008 | 39 | 0.080 |
Why?
|
Radiosurgery | 1 | 2011 | 272 | 0.080 |
Why?
|
Tumor Burden | 1 | 2009 | 289 | 0.080 |
Why?
|
History, 21st Century | 1 | 2009 | 175 | 0.080 |
Why?
|
Quality of Life | 1 | 2016 | 1585 | 0.080 |
Why?
|
History, 20th Century | 1 | 2009 | 312 | 0.080 |
Why?
|
Platinum Compounds | 1 | 2007 | 31 | 0.080 |
Why?
|
Drug Administration Schedule | 1 | 2009 | 916 | 0.080 |
Why?
|
Treatment Failure | 2 | 2006 | 285 | 0.080 |
Why?
|
Ligands | 1 | 2008 | 433 | 0.080 |
Why?
|
Genes, BRCA2 | 1 | 2008 | 160 | 0.070 |
Why?
|
Glutamates | 1 | 2007 | 89 | 0.070 |
Why?
|
Dacryocystorhinostomy | 1 | 2006 | 4 | 0.070 |
Why?
|
Silicones | 1 | 2006 | 16 | 0.070 |
Why?
|
Guanine | 1 | 2007 | 208 | 0.070 |
Why?
|
Carboplatin | 1 | 2007 | 286 | 0.070 |
Why?
|
Fibroblasts | 1 | 2008 | 729 | 0.070 |
Why?
|
Cohort Studies | 3 | 2017 | 2767 | 0.060 |
Why?
|
London | 1 | 2004 | 16 | 0.060 |
Why?
|
Bacteriophage M13 | 1 | 2004 | 9 | 0.060 |
Why?
|
Adolescent | 3 | 2007 | 8981 | 0.060 |
Why?
|
Safe Sex | 1 | 2004 | 23 | 0.060 |
Why?
|
Pregnancy in Adolescence | 1 | 2004 | 25 | 0.060 |
Why?
|
Condoms | 1 | 2004 | 36 | 0.060 |
Why?
|
Sex Distribution | 1 | 2004 | 173 | 0.060 |
Why?
|
Radiation, Ionizing | 1 | 2004 | 121 | 0.060 |
Why?
|
Peptide Library | 1 | 2004 | 84 | 0.060 |
Why?
|
Focus Groups | 1 | 2004 | 155 | 0.060 |
Why?
|
Awareness | 1 | 2004 | 93 | 0.060 |
Why?
|
Risk Reduction Behavior | 1 | 2004 | 98 | 0.060 |
Why?
|
Radiation Tolerance | 1 | 2004 | 168 | 0.060 |
Why?
|
Pilot Projects | 1 | 2006 | 839 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2007 | 1753 | 0.060 |
Why?
|
Stents | 1 | 2006 | 377 | 0.060 |
Why?
|
HIV Infections | 1 | 2011 | 772 | 0.060 |
Why?
|
Infant, Newborn | 1 | 2008 | 2379 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2003 | 155 | 0.050 |
Why?
|
Recombinant Fusion Proteins | 1 | 2004 | 557 | 0.050 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2001 | 12 | 0.050 |
Why?
|
Genetic Vectors | 1 | 2003 | 439 | 0.050 |
Why?
|
Platinum | 1 | 2021 | 63 | 0.050 |
Why?
|
Young Adult | 2 | 2013 | 5976 | 0.050 |
Why?
|
Vaginal Neoplasms | 1 | 2001 | 83 | 0.050 |
Why?
|
Infant | 1 | 2007 | 3046 | 0.050 |
Why?
|
China | 1 | 2021 | 228 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2019 | 1578 | 0.050 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2021 | 416 | 0.050 |
Why?
|
Cryoelectron Microscopy | 1 | 2021 | 91 | 0.050 |
Why?
|
Child, Preschool | 1 | 2007 | 3612 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2016 | 1961 | 0.050 |
Why?
|
Vascular Neoplasms | 1 | 2000 | 19 | 0.050 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2001 | 150 | 0.050 |
Why?
|
Nucleic Acid Conformation | 1 | 2021 | 332 | 0.050 |
Why?
|
Socioeconomic Factors | 2 | 1999 | 567 | 0.050 |
Why?
|
Risk Assessment | 1 | 2007 | 2261 | 0.050 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2000 | 100 | 0.050 |
Why?
|
Carcinoma | 2 | 2000 | 436 | 0.050 |
Why?
|
Knee Prosthesis | 1 | 2019 | 33 | 0.040 |
Why?
|
Molecular Dynamics Simulation | 1 | 2021 | 245 | 0.040 |
Why?
|
Oxygen | 1 | 2004 | 726 | 0.040 |
Why?
|
Cell Line | 2 | 2016 | 2468 | 0.040 |
Why?
|
Molecular Sequence Data | 1 | 2004 | 3030 | 0.040 |
Why?
|
Vagina | 1 | 2000 | 161 | 0.040 |
Why?
|
Protein Conformation | 1 | 2021 | 881 | 0.040 |
Why?
|
Heterografts | 1 | 2019 | 98 | 0.040 |
Why?
|
Analysis of Variance | 1 | 2001 | 912 | 0.040 |
Why?
|
Arthroplasty, Replacement, Knee | 1 | 2019 | 111 | 0.040 |
Why?
|
Hodgkin Disease | 1 | 1999 | 177 | 0.040 |
Why?
|
Pregnancy | 1 | 2004 | 2894 | 0.040 |
Why?
|
Radiation Dosage | 2 | 2011 | 227 | 0.030 |
Why?
|
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2015 | 17 | 0.030 |
Why?
|
Stilbenes | 1 | 2015 | 25 | 0.030 |
Why?
|
Aptamers, Nucleotide | 1 | 2015 | 23 | 0.030 |
Why?
|
Mutagens | 1 | 2015 | 31 | 0.030 |
Why?
|
Replication Protein A | 1 | 2015 | 16 | 0.030 |
Why?
|
Virus Internalization | 1 | 2015 | 39 | 0.030 |
Why?
|
Remission Induction | 2 | 2011 | 722 | 0.030 |
Why?
|
DNA, Neoplasm | 1 | 2015 | 265 | 0.030 |
Why?
|
Ovarian Neoplasms | 1 | 2000 | 744 | 0.030 |
Why?
|
Virus Replication | 1 | 2015 | 319 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2015 | 547 | 0.030 |
Why?
|
SEER Program | 1 | 2013 | 190 | 0.030 |
Why?
|
HIV Integrase | 1 | 2011 | 5 | 0.030 |
Why?
|
Four-Dimensional Computed Tomography | 1 | 2011 | 18 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2013 | 357 | 0.030 |
Why?
|
Maximum Tolerated Dose | 1 | 2011 | 270 | 0.020 |
Why?
|
Gene Expression | 1 | 2015 | 1284 | 0.020 |
Why?
|
Time Factors | 1 | 1999 | 5210 | 0.020 |
Why?
|
Risk Factors | 1 | 2001 | 5417 | 0.020 |
Why?
|
Recombination, Genetic | 1 | 2011 | 439 | 0.020 |
Why?
|
Chemoradiotherapy | 1 | 2011 | 301 | 0.020 |
Why?
|
Pemetrexed | 1 | 2007 | 76 | 0.020 |
Why?
|
Disease Progression | 1 | 2011 | 1531 | 0.020 |
Why?
|
Area Under Curve | 1 | 2007 | 334 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2012 | 1204 | 0.020 |
Why?
|
Prospective Studies | 1 | 2012 | 4213 | 0.010 |
Why?
|
Models, Biological | 1 | 2008 | 1749 | 0.010 |
Why?
|
Morbidity | 1 | 2000 | 148 | 0.010 |
Why?
|
Fever | 1 | 2000 | 125 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2000 | 146 | 0.010 |
Why?
|
Mutation | 1 | 2008 | 3968 | 0.010 |
Why?
|
Hospitalization | 1 | 2000 | 849 | 0.010 |
Why?
|